Physician profile
John P Klim
NPI 1508834672
$7,538.13
in general payments reported to CMS, 2019-2025
34 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $337 · 2021: $385 · 2022: $1,816 · 2023: $821 · 2024: $2,740 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Travel and Lodging: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.70 |
| Travel and Lodging | $1,734.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,389.42 | 2024 | |
| Relievant Medsystems, INC. | $1,373.14 | 2020-2023 | Intracept |
| Curonix LLC | $946.54 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $586.94 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $549.83 | 2019-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $282.43 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $279.14 | 2021-2022 | |
| Abbott Laboratories | $271.80 | 2019-2025 | Eterna, Proclaim |
| Arbor Pharmaceuticals, INC. | $250.06 | 2020-2021 | |
| Medtronic, INC. | $198.98 | 2022-2024 | Venaseal, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Spr Therapeutics, INC | $150.35 | 2023-2025 | Sprint Pns System |
| Nevro Corp. | $148.41 | 2019 | |
| Globus Medical, INC. | $134.81 | 2025 | Senza, Vyrsa V1 |
| Pfizer INC. | $112.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $105.26 | 2024-2025 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $90.29 | 2020-2022 | |
| Amgen INC. | $77.21 | 2022-2023 | Evenity |
| Spinal Simplicity, LLC | $66.76 | 2025 | Ha Minuteman G3-R |
| Vertex Pharmaceuticals Incorporated | $55.80 | 2025 | |
| Abbvie INC. | $53.88 | 2022-2023 | |
| Indivior INC. | $52.92 | 2019-2020 | |
| Bioventus LLC | $48.39 | 2022-2025 | Xcell |
| Stryker Corporation | $45.18 | 2023 | Viaflow |
| Painteq LLC | $38.07 | 2024 | Painteq |
| Valinor Pharma, LLC | $36.87 | 2025 | Movantik |
| Lundbeck LLC | $32.40 | 2024 | Vyepti |
| Orexo US, INC. | $32.03 | 2022-2025 | Zubsolv |
| Scilex Pharmaceuticals INC. | $21.43 | 2025 | |
| Tonix Medicines, INC. | $21.30 | 2025 | Tonmya |
| Angiodynamics, INC. | $19.94 | 2023 | Venacure 1470 Pro |
| Saluda Medical Americas, INC. | $17.07 | 2024 | Evoke |
| Medline Industries LP | $17.00 | 2023 | |
| Mml US, INC. | $15.93 | 2023 | Reactiv8 |
| Idorsia Pharmaceuticals US INC | $15.76 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Klim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.